1AF24109-5FE4-4868-ADB9-5DFDB57BCA0F
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.542
- G2M_CHECKPOINT+0.537
- E2F_TARGETS+0.510
- MYC_TARGETS_V1+0.462
- WNT_BETA_CATENIN_SIGNALING+0.430
- TGF_BETA_SIGNALING+0.396
- NOTCH_SIGNALING+0.384
- DNA_REPAIR+0.374
- UNFOLDED_PROTEIN_RESPONSE+0.354
- MITOTIC_SPINDLE+0.312
Top 10 suppressed
- KRAS_SIGNALING_DN-0.393
- MYOGENESIS-0.337
- PANCREAS_BETA_CELLS-0.290
- COAGULATION-0.288
- INFLAMMATORY_RESPONSE-0.254
- INTERFERON_GAMMA_RESPONSE-0.248
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.246
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.228
- APICAL_SURFACE-0.220
- ESTROGEN_RESPONSE_LATE-0.199
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | D902E43A-F384-432A-B690-D20BFCC78443 | — | — | 0.913 |
| 2 | DD028798-C4CB-43A8-81D7-711E015E23B5 | — | — | 0.904 |
| 3 | F56466DC-3C0F-48BE-8A72-CEDEAEF52F00 | — | — | 0.900 |
| 4 | A1E55AC6-A41F-454A-A3B6-8F49D2AAFEF2 | — | — | 0.895 |
| 5 | SRR934853 | — | — | 0.891 |
| 6 | 8B2B5542-3E54-4643-BB57-0BEFCF89A16B | — | — | 0.891 |
| 7 | 4F62A177-D1C6-4829-A86E-7CA1D29421FC | — | — | 0.889 |
| 8 | SRR934880 | — | — | 0.888 |
| 9 | SRR934744 | — | — | 0.888 |
| 10 | D38D3FD9-7A58-43D0-876C-6235DA833043 | — | — | 0.887 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.542 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.537 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.462 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.430 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.396 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.384 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.374 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.354 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.312 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.201 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.184 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.083 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.061 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.046 | Inavolisib | — uncovered |
| APOPTOSIS | 0.030 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.018 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.017 | Inavolisib | — uncovered |
| PEROXISOME | 0.014 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.011 | Idelalisib | — uncovered |